Senate ‘Innovation’ Bill Being Narrowed With Year-End Committee Passage In Mind
This article was originally published in The Tan Sheet
The counterpart to the House Cures bill likely will focus on ‘big buckets’ of issues, including new approval pathway for antibiotics, reforms at NIH and biomarker development.
You may also be interested in...
CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.
Mark McClellan discusses whether CMS’s pending final version of the Medicare national coverage determination on Alzheimer’s drugs might change from the draft and whether the decision should be viewed as a precedent for drugs granted accelerated approvals.
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.